Clinical therapeutics
-
Clinical therapeutics · May 1995
Randomized Controlled Trial Multicenter Study Clinical TrialUse of anesthesia selection in controlling surgery costs in an HMO hospital.
The cost of induction and maintenance of anesthesia is analyzed in this article from the perspective of a health maintenance organization's (HMO) chief financial officer. While earlier economic studies tended to focus on the raw cost of anesthesia drugs, our model also includes the cost of the clinical labor involved in administering the drug as well as the fixed costs associated with the facility. Such a model is consistent with the goal of an HMO, which is to provide high-quality health care services to its membership while containing costs. ⋯ Because institutional pricing policies differ greatly, only the findings at the HMO hospital are presented in this report. Our results suggest that intra-abdominal surgical procedures with a duration of less than 4 hours that use propofol for induction and maintenance of anesthesia reduce the total cost of surgery by $202.71, compared with the costs of using thiopental/isoflurane. Sensitivity analysis maintains the robustness of the conclusions with regard to all major parameters.
-
Clinical therapeutics · May 1995
Multicenter Study Clinical TrialMulticenter, phase IV evaluation of intravenous ciprofloxacin as initial therapy in patients with lower respiratory tract, urinary tract, and skin/skin structure infections.
A prospective, open-label, multicenter, Phase IV study of the efficacy and safety of intravenous (IV) ciprofloxacin (400 mg by 60-minute infusion every 12 hours) in the treatment of lower respiratory tract infections (LRTIs), urinary tract infections (UTIs), and skin/skin structure infections (SSSIs) in hospitalized patients was conducted in 1991. After a minimum of 3 days of IV therapy, patients could be switched to oral therapy with any antimicrobial. ⋯ Adverse events were noted in 72 (9%) of 782 patients and led to premature discontinuation of IV therapy in 23 (3%) patients. IV ciprofloxacin appears to be effective and safe in the management of mild-to-moderate LRTI and SSSI and mild, moderate, or severe UTI in hospitalized patients.